Additionally, based on Sun et al. study, BRCA1/BRCA2/PALB2 testing for all cases having breast cancer were compared with the current BRCA testing based on the clinical criteria or the FH alone which were cost-effective [9, 32]. The gene discussed is PALB2; the disease is breast cancer.